Quitting Matters Human Immunodeficiency Virus Hybrid Trial

Launched by WAKE FOREST UNIVERSITY HEALTH SCIENCES · Mar 12, 2025

Keywords

ClinConnect Summary

Tobacco use has alarmingly high rates among people with Human Immunodeficiency Virus (HIV) (PWH), 43% compared with 15% in the general population. Due to the development of highly effective treatments for HIV and the resulting increased longevity among PWH, this population now loses more life years to smoking than to HIV infection itself. Novel and effective models to deliver wider reaching smoking cessation interventions for PWH are highly needed and indicated as a priority for National Institute of Health. Digital therapeutics (DTx) may be a novel, scalable, and highly available approach ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Self-reported daily cigarette smoking over the past 30 days
• • 2. Self-reported HIV status
• • 3. Age 18 or older
• • 4. Desire to quit smoking
• • 5. Willing and medically eligible to use NRT
• • 6. Currently receiving HIV care
• • 7. Currently owning an Android or iOS smartphone
• Exclusion Criteria:
• • 1. Current acute psychotic episode or unsafe to participate in the study
• • 2. Pregnant or intending to become pregnant in the next 6 months
• • 3. Currently receiving any pharmacological and/or behavioral intervention or counseling for smoking cessation
• • 4. Any medical condition or medication that could compromise subject safety, as determined by the PIs and/or study physician
• • 5. Not able to fluently speak and write in English
• • 6. Hearing, comprehension, visual, speech, or motor limitations that preclude study participation

Trial Officials